688443.SHG Chongqing Genrix Biopharmaceutical Co. Ltd. A

Healthcare Biotechnology Shanghai Stock Exchange
27.58 CNY
Close of Nov 4, 2026
20.07 32.82
Market cap
CNY 10.1B
P/E
-
P/B
7.24x
ROE
-49.3%
Dividend yield
0.30%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 688443.SHG undervalued?

Graham number

The Graham number of Chongqing Genrix Biopharmaceutical Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Chongqing Genrix Biopharmaceutical Co. Ltd. A fundamental analysis

No fundamental analysis for Chongqing Genrix Biopharmaceutical Co. Ltd. A yet.

Chongqing Genrix Biopharmaceutical Co. Ltd. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Chongqing Genrix Biopharmaceutical Co. Ltd. A

Chongqing Genrix Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs in China. It develops GR1501, a monoclonal antibody for the treatment of axial spondyloarthritis; GR1801, an anti-rabies virus G protein bispecific antibody; GR1802, an anti-IL-4Ra monoclonal antibody; GR1603, a monoclonal antibody for systemic lupus erythematosus; GR2002 an anti-TSLP bispecific antibody; WM1R3, a family r…

Full company profile